EuropeanRegulatory GateUpdated daily
European funding rounds in hardware and deep tech, new funds and public programmes, open calls, and the EU rules that change how founders raise capital — each with a short note on why it matters and a link to the source.
21 items
Edinburgh- and Boston-based Bioliberty raised a €2.95 million Series A extension for its AI-powered home rehabilitation technology, bringing total funding to €12.07 million. New institutional backers joined, showing continued investor interest in European medtech/rehab hardware startups.
Tech.eu reports on Europe's 10 most-funded healthtech companies in H1 2026, noting large rounds in biotech, medical devices and AI-powered healthcare with the UK leading investment. This market data helps founders and investors benchmark where healthtech capital is flowing in Europe.
Copenhagen-based Biograil raised €20 million to develop an oral device for delivering therapeutics that normally require injection. The round was backed by Verve Ventures, Megatrend Invest and HTGF's Opportunity growth fund, giving the medtech company fresh capital to advance its drug-delivery device.
Leipzig-based JawBuddy raised €818k in a pre-seed round led by HALBZEIT, with backing from dental and maxillofacial specialists, to develop a device-based solution for jaw pain, bruxism and TMJ tension. It's a small but notable medtech seed round for founders tracking European hardware-health funding activity.
Scottish drug-delivery device maker 1nhaler raised £2.2 million in follow-on funding led by Archangels to advance its cardboard pop-up inhaler toward first regulatory approval. It's a concrete example of a European medtech hardware startup securing growth capital ahead of regulatory milestones.
Italian deeptech startup Magic Vision raised €600,000 to develop and commercialise its AI-powered monitoring technology, Silver Eye, aimed at older and vulnerable people. The small round shows continued early-stage investor interest in AI-enabled hardware for elderly care, a niche within European medtech.
Spanish digital orthodontics network Impress signed a €40 million venture debt loan with the EIB to expand its clinic network and AI platform across Europe. It shows EIB continuing to back scale-ups in medtech-adjacent physical-product businesses with non-dilutive debt.
Swiss medtech startup CHD received about €160,000 from Venture Kick to advance its remote maternal and fetal monitoring technology. It's an early, non-dilutive boost for a European deep-tech medical device company scaling its solution.
University of Leeds spinout adsilico raised £10 million in a Series A round to expand its AI-powered simulation technology that tests medical device performance on virtual patients. It's a fresh capital injection for a UK medtech deep-tech company serving device makers and regulators.
London-based surgical intelligence company XRlabs raised €7.48 million in seed funding led by Playground Global to bring AI into the operating room. It signals growing deep-tech investor interest in AI-enabled medical devices and surgical tools.
London-based Unravel Health raised €2.96 million to develop a palm-sized at-home hormone testing device, led by Conduit EIS Impact Fund and Wrightwood. The round shows continued investor interest in European hardware-based medtech diagnostics for consumer health.
Milan's Panakès Partners launched an €8.5 million investment vehicle funded by Lombardia Venture STEP, the Lombardy Region's fund of funds, to back life sciences, MedTech and BioTech companies. This creates a new regional capital source for European medtech and biotech founders seeking early-stage investment.
Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics, raised a €16 million seed round co-led by 4BIO Capital and IQ Capital to develop its AI-enabled DELiveri platform for targeted RNA medicines beyond the liver. This is a European biotech deep-tech round relevant to medtech-focused founders and investors.
Scarlet, a certification body for AI and software medical devices, raised a $50 million Series B led by Headline with participation from Notion Capital and existing investors. As a software/service certification provider rather than a hardware maker, it's relevant mainly as a funding data point, not a physical-product deal.
Ghent-based SpectaCell, a spin-out from imec, VIB and Ghent University, raised €6 million in Seed funding led by imec.xpand to advance its cell analysis platform for immunotherapy development. It's a fresh example of European deep-tech biotech spin-outs attracting early institutional backing.
London-based Sava Technologies raised a €32.08 million Series B led by Ascensia to fund manufacturing scale-up and commercial readiness for its wearable glucose microsensor platform, partnering with Ascensia for European distribution. It shows continued European investor appetite for physical medtech hardware nearing commercialisation.
MintNeuro, an Imperial College London spinout, raised $5m to scale chips purpose-built for neural devices such as implants and wearables. This is a clear hardware/medtech deep-tech round relevant to founders building neurotech devices.
Danish clinical-stage biopharma Breye Therapeutics closed an oversubscribed €67.5 million Series A to advance oral therapies for early retinal disease treatment, co-led by Mission BioCapital and Novo Holdings. It's a sizeable European medtech/biotech raise relevant to founders and investors tracking deep-tech healthcare funding.
Milan-based biotech Aptadir Therapeutics raised a $45 million seed round to develop treatments for difficult-to-treat genetic conditions. It is a significant biotech seed round relevant to European deep-tech and medtech founders.
Paris-based Sofinnova Partners closed its oversubscribed €82M MD Start IV fund, continuing a strategy since 2008 to build new medtech companies from scratch. This gives European medtech founders another dedicated company-building vehicle to approach for early capital.
Items are selected and summarised automatically from public sources once a day. The summary is ours; the facts belong to the linked source — check it before acting. This is market information, not investment or legal advice.